Hot on the heels of its completion of a clinical trial in people with Type 2 diabetes, CeQur has received a CE mark for its PaQ insulin delivery device, allowing it to be marketed in Europe.
CeQur's wearable insulin pump provides three days' worth of continuous insulin as well as on-demand bolus insulin to top up levels for mealtimes. It can be hidden easily and is simple to use, with a reusable insulin monitor and disposable insulin infuser and reservoir.
Jay Warner, senior vice president of clinical development and commercialization, told Mass High Tech that CeQur plans an initial and limited launch next year, with a wider launch in Europe planned for 2014 after further clinical trials. The company expects to submit for approval in the U.S. next year.
Many people with Type 2 diabetes cannot control their disease with drugs and diet alone and so require daily injections of insulin. About half of people who need daily shots of insulin skip doses because of the pain, inconvenience or embarrassment of having to inject the drug. Insulin pumps can reduce the inconvenience for patients and improve their compliance with their treatment, thereby cutting their chances of long-term problems such as blindness or kidney disease.